Vorasidenib citrateProduct ingredient for Vorasidenib
- Name
- Vorasidenib citrate
- Drug Entry
- Vorasidenib
Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor.1 It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.6 Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as ivosidenib and enasidenib.1
Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.7
- Accession Number
- DBSALT003529
- Structure
Structure for Vorasidenib citrate (DBSALT003529)
- Synonyms
- 1,3,5-TRIAZINE-2,4-DIAMINE, 6-(6-CHLORO-2-PYRIDINYL)-N2,N4-BIS((1R)-2,2,2-TRIFLUORO-1-METHYLETHYL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE, HYDRATE (2:1:1) / 6-(6-Chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine, 2-hydroxypropane-1,2,3-tricarboxylate, hydrate (2:1:1) / AG-881 HEMICITRATE HEMIHYDRATE / Vorasidenib citrate / VORASIDENIB HEMICITRATE HEMIHYDRATE